Understanding Microsatellite Instability in Rectal Cancer
The U.S. Food and Drug Administration granted accelerated approval to the PD-1 inhibitor dostarlimab, marketed as Jemperli, for the treatment of adult patients with stage II or III locally advanced rectal cancer that is microsatellite instability-high or mismatch repair-deficient. For patients and their families facing a daunting cancer diagnosis, this regulatory decision brings a profound human shift in how doctors approach treatment plans. Behind the medical terminology lies a specific biological marker that changes whether a patient must endure traditional surgery, radiation, and chemotherapy.
Microsatellite instability-high status reflects defective DNA mismatch repair, a molecular phenotype that shapes both prognosis and immunotherapy eligibility. Every day in clinics, doctors see how errors in genetic spelling can disrupt normal cellular growth. When cells fail to repair these DNA mismatches, abnormal repetitive DNA sequences accumulate, creating a molecular signature known as microsatellite instability. This specific genetic profile makes tumors highly immunogenic, meaning the body’s immune system can be trained to recognize and destroy the cancer cells when stimulated by the right medication.
How Testing and Biology Guide Personalized Care
Determining microsatellite instability status requires a meticulous multi-step laboratory effort to examine tumor tissue closely. According to data published in October 2026, laboratory staff take formalin-fixed, paraffin-embedded tumor sections of four micrometers and stain them by automated immunohistochemistry for four key mismatch repair proteins: MLH1, MSH2, MSH6, and PMS2. Internal positive controls, including non-neoplastic crypt epithelium, intratumoral lymphocytes, and stromal cells, must show unambiguous nuclear staining before a slide can be scored. Complete absence of staining in tumor cells, with intact internal controls, is interpreted as loss of expression, while heterogeneous or focal patterns are classified as retained but flagged for independent secondary review.
When immunohistochemistry cannot resolve status, secondary methods provide clarity for the medical team. Technicians perform polymerase chain reaction assays targeting a pentaplex panel of mononucleotide markers, including BAT-25, BAT-26, NR-21, NR-24, and NR-27, on the original tumor samples. Instability at two or more markers defines microsatellite instability-high status. Furthermore, second primary colorectal cancers in survivors often lack robust data on this status, making new datasets from researchers in Hebei, China, critical for understanding tumor biology and ensuring patients receive accurate evaluations.
Clinical Trial Results and What the Data Shows
The approval of dostarlimab followed a priority review supported by results from the phase 2 AZUR-1 trial, registered as ClinicalTrials.gov identifier NCT05723562. This multicenter, single-arm, open-label trial evaluated 154 previously untreated patients with histologically confirmed, stage II or III microsatellite instability-high or mismatch repair-deficient locally advanced rectal cancer. Patients received dostarlimab at a dose of 500 mg intravenously every three weeks for nine cycles, unless unacceptable toxicity or disease progression occurred. Tumor response was assessed using endoscopy, rectal magnetic resonance imaging, and computed tomography scans of the chest, abdomen, and pelvis at week 6, week 12, and approximately three weeks after completing treatment.
The numbers from the trial offer a clear picture of how biomarker-driven therapy alters patient outcomes. In findings evaluated by independent central review, the objective response rate reached 79 percent, and 47 percent of patients achieved a sustained clinical complete response lasting at least 12 months. At a median follow-up of 26.3 months, 110 out of 154 patients, representing 71 percent, received dostarlimab alone without any additional form of treatment and experienced no disease progression. Another 26 patients underwent surgery, 13 received additional systemic therapy or radiation, one had progressive disease without further treatment, and four withdrew or were lost to follow-up.
For patients who achieved a clinical complete response, the ongoing care plan involves close monitoring through regular multimodal assessments conducted every four months for the first two years, before switching to assessments every six months. Among 15 patients who underwent surgery after dostarlimab because imaging suggested an incomplete response, 12 achieved a pathological complete response. At the data cutoff, 38 additional patients had achieved a clinical complete response with less than 12 months of follow-up, while 44 had achieved a near-complete response. The data do not yet show long-term overall survival figures or long-term safety outside the median follow-up of 26.3 months, and non-responders still required standard surgery or chemoradiation. If you or a loved one are navigating a rectal cancer diagnosis, talk to your doctor or oncologist to understand your molecular testing options and what personalized therapy means for your health.
Long-Term Outcomes and Ongoing Monitoring Requirements
Long-term follow-up data from the AZUR-1 trial continues to shape the evolving standard of care for MSI-H/dMMR rectal cancer patients. At the data cutoff, 38 additional patients had achieved a clinical complete response with less than 12 months of follow-up, while 44 had achieved a near-complete response. Among the 15 patients who underwent surgery after dostarlimab due to imaging suggesting an incomplete response, 12 achieved a pathological complete response, underscoring the potential for de-escalation of aggressive local therapies. However, the data do not yet show long-term overall survival figures or long-term safety profiles beyond the median follow-up of 26.3 months, and non-responders still required standard surgery or chemoradiation. For patients who achieved a clinical complete response, the ongoing care plan involves close monitoring through regular multimodal assessments conducted every four months for the first two years, before switching to assessments every six months. This structured surveillance protocol reflects the necessity of vigilant monitoring given the possibility of late recurrences, even among patients who initially demonstrated robust responses to immunotherapy.
Clinical guidelines emphasize that treatment decisions remain individualized based on patient response and disease trajectory. Patients who did not experience a clinical complete response, or whose disease recurred or progressed, were evaluated for standard-of-care management at investigator discretion. The ongoing monitoring strategy, combined with the demonstrated ability of dostarlimab to induce durable responses in a significant subset of patients, represents a paradigm shift toward biomarker-driven de-escalation of treatment. As researchers in Hebei, China, have noted in their analysis of second primary colorectal cancers, the long-term biological behavior of these tumors remains an area requiring further investigation, particularly as survival rates improve and the incidence of subsequent malignancies grows.
Sources
- New Dataset Profiles Microsatellite Instability in Colorectal Cancers That
- FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
- Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer | Targeted Oncology – Immunotherapy, Biomarkers, and Cancer Pathways
Photo: Chris j wood (CC BY-SA 4.0)
